NASDAQ:TNGX Tango Therapeutics (TNGX) Stock Price, News & Analysis $10.89 -0.79 (-6.76%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$10.84▼$11.9250-Day Range$8.10▼$11.9352-Week Range$5.15▼$13.03Volume509,680 shsAverage Volume675,295 shsMarket Capitalization$1.16 billionP/E RatioN/ADividend YieldN/APrice Target$15.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Tango Therapeutics alerts: Email Address Tango Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.13 Rating ScoreUpside/Downside39.1% Upside$15.14 Price TargetShort InterestBearish17.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 7 Articles This WeekInsider TradingSelling Shares$16.70 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.31) to ($1.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.22 out of 5 starsMedical Sector708th out of 910 stocksPharmaceutical Preparations Industry332nd out of 426 stocks 3.6 Analyst's Opinion Consensus RatingTango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTango Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Tango Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.69% of the float of Tango Therapeutics has been sold short.Short Interest Ratio / Days to CoverTango Therapeutics has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.Change versus previous monthShort interest in Tango Therapeutics has recently increased by 10.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTango Therapeutics does not currently pay a dividend.Dividend GrowthTango Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TNGX. Previous Next 2.4 News and Social Media Coverage News SentimentTango Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Tango Therapeutics this week, compared to 2 articles on an average week.Search Interest5 people have searched for TNGX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tango Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,696,385.00 in company stock.Percentage Held by InsidersOnly 6.20% of the stock of Tango Therapeutics is held by insiders.Percentage Held by Institutions78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tango Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tango Therapeutics are expected to decrease in the coming year, from ($1.31) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tango Therapeutics is -9.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tango Therapeutics is -9.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTango Therapeutics has a P/B Ratio of 4.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tango Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Tango Therapeutics Stock (NASDAQ:TNGX)Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.Read More TNGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TNGX Stock News HeadlinesSeptember 5 at 6:37 AM | insidertrades.comTango Therapeutics, Inc. (NASDAQ:TNGX) Major Shareholder Rock Ventures Iv L.P. Third Sells 175,000 SharesAugust 30, 2024 | insidertrades.comTango Therapeutics, Inc. (NASDAQ:TNGX) Major Shareholder Sells $288,750.00 in StockSeptember 7, 2024 | True Gold Republic (Ad)China Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . August 21, 2024 | insidertrades.comRock Ventures Iv L.P. Third Sells 135,000 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) StockSeptember 6 at 4:25 AM | americanbankingnews.comRock Ventures Iv L.P. Third Sells 175,000 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) StockSeptember 4 at 1:15 AM | americanbankingnews.comTango Therapeutics, Inc. (NASDAQ:TNGX) Receives $15.14 Consensus Price Target from BrokeragesAugust 31, 2024 | americanbankingnews.comRock Ventures Iv L.P. Third Sells 25,000 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) StockAugust 18, 2024 | finance.yahoo.comTNGX Nov 2024 10.000 put (TNGX241115P00010000)September 7, 2024 | True Gold Republic (Ad)China Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . August 18, 2024 | msn.comJefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ StocksAugust 8, 2024 | benzinga.comAnalyst Expectations For Tango Therapeutics's FutureAugust 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Inozyme Pharma (INZY) and Foghorn Therapeutics (FHTX)August 7, 2024 | finance.yahoo.comTango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business HighlightsJuly 19, 2024 | msn.comJefferies Initiates Coverage of Tango Therapeutics (TNGX) with Buy RecommendationJune 5, 2024 | businesswire.comTango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Medtronic (MDT), Crispr Therapeutics AG (CRSP) and Tango Therapeutics (TNGX)May 23, 2024 | prnewswire.comMedivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical programMay 23, 2024 | reuters.comTango Therapeutics to stop development of cancer therapySee More Headlines Receive TNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNGX CUSIPN/A CIK1819133 Webwww.tangotx.com Phone857-320-4900FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$15.14 High Stock Price Target$19.00 Low Stock Price Target$13.00 Potential Upside/Downside+39.1%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,740,000.00 Net Margins-274.04% Pretax Margin-273.63% Return on Equity-44.73% Return on Assets-28.79% Debt Debt-to-Equity RatioN/A Current Ratio7.49 Quick Ratio7.49 Sales & Book Value Annual Sales$42.51 million Price / Sales27.37 Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book4.71Miscellaneous Outstanding Shares106,846,000Free Float100,222,000Market Cap$1.16 billion OptionableOptionable Beta0.84 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Barbara L. Weber M.D. (Age 67)President, CEO & Director Comp: $1.04MDr. Adam S. Crystal M.D. (Age 47)Ph.D., President of Research & Development Comp: $977.22kDr. Alan Ashworth FRS (Age 63)Ph.D., Founder & Member of Scientific Advisory Board Dr. Levi Garraway M.D. (Age 55)Ph.D., Founder Dr. William G. Kaelin Jr. (Age 66)M.D., Founder & Member of Scientific Advisory Board Dr. Timothy K. Lu M.D. (Age 43)Ph.D., Founder Dr. Antoni Ribas M.D. (Age 57)Ph.D., Founder & Member of Scientific Advisory Board Mr. Timothy Redfern (Age 45)Chief Financial Officer Mr. Jannik N. Andersen Ph.D.Chief Scientific OfficerMr. Douglas J. Barry Esq. (Age 54)J.D., Chief Legal Officer, Chief Compliance Officer & Corporate Secretary More ExecutivesKey CompetitorsCompoSecureNASDAQ:CMPOEos Energy EnterprisesNASDAQ:EOSEDocGoNASDAQ:DCGOOusterNYSE:OUSTOrigin MaterialsNASDAQ:ORGNView All CompetitorsInsiders & InstitutionsRock Ventures Iv L.P. ThirdSold 175,000 sharesTotal: $2.03 M ($11.60/share)Rock Ventures Iv L.P. ThirdSold 25,000 sharesTotal: $288,750.00 ($11.55/share)Rock Ventures Iv L.P. ThirdSold 150,000 sharesTotal: $1.51 M ($10.09/share)Point72 Asset Management L.P.Bought 447,107 shares on 8/19/2024Ownership: 0.418%Rock Ventures Iv L.P. ThirdSold 135,000 sharesTotal: $1.32 M ($9.79/share)View All Insider TransactionsView All Institutional Transactions TNGX Stock Analysis - Frequently Asked Questions How have TNGX shares performed this year? Tango Therapeutics' stock was trading at $9.90 at the beginning of 2024. Since then, TNGX stock has increased by 10.0% and is now trading at $10.89. View the best growth stocks for 2024 here. How were Tango Therapeutics' earnings last quarter? Tango Therapeutics, Inc. (NASDAQ:TNGX) released its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.10. The company earned $19.88 million during the quarter, compared to analysts' expectations of $7.39 million. Tango Therapeutics had a negative trailing twelve-month return on equity of 44.73% and a negative net margin of 274.04%. Who are Tango Therapeutics' major shareholders? Tango Therapeutics' top institutional shareholders include Point72 Asset Management L.P. (0.42%), Dimensional Fund Advisors LP (0.31%), Ensign Peak Advisors Inc (0.25%) and Bank of New York Mellon Corp (0.13%). Insiders that own company stock include Rock Ventures Iv LP Third, Boxer Capital, Llc, Mva Investors, Llc, Daniella Beckman and Douglas Barry. View institutional ownership trends. How do I buy shares of Tango Therapeutics? Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TNGX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.